

Docket No.: TRIPEP.23AUSC2

Customer No. 20,995

IFW \$

INFORMATION DISCLOSURE STATEMENT

Applicant : Sallberg, et al.
App. No : 10/719,619
Filed : November 20, 2003
For : VACCINES CONTAINING
RIBAVIRIN AND METHODS OF USE
THEREOF
Examiner : Bao Q. Li
Art Unit : 1648

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

2/7/07

(Date)

ES
Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 79 references to be considered by the Examiner. Also enclosed are 55 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/7/07

By: *ES*


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

02/26/2007 RHEBRAHT 00000011 10719619

01 FC:1806

180.00 OP

3334193
012207



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 1 OF 4	Attorney Docket No.	TRIEP.23AUSC2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,215,051	7/29/1980	Schroeder et al.	
	2	4,376,110	3/8/1983	David et al.	
	3	4,486,530	12/4/1984	David et al.	
	4	4,683,195	7/28/1987	Mullis et al.	
	5	4,683,202	7/28/1987	Mullis, Kary B.	
	6	4,818,540	4/4/1989	Chien, et al.	
	7	4,873,191	10/10/1989	Wagner et al.	
	8	4,965,188	10/23/1990	Mullis, Kary B.	
	9	5,143,854	9/1/1992	Pirrung et al	
	10	5,290,678	3/1/1994	Jackowski	
	11	5,322,770	6/21/1994	Gelfand	
	12	5,412,087	5/2/1995	McGall et al.	
	13	5,593,972	1/14/1997	Weiner et al.	
	14	5,604,105	2/18/1997	Jackowski	
	15	5,710,008	1/20/1998	Jackowski	
	16	5,739,118	4/14/1998	Carrano et al.	
	17	5,744,358	4/28/1998	Jackowski	
	18	5,747,274	5/5/1998	Jackowski	
	19	5,847,101	12/1/1998	Okayama et al	
	20	5,879,904	3/1/1999	Brechot et al.	
	21	6,153,421	11/1/2000	Yanagi et al.	
	22	2004/0092730	5/13/2004	Sallberg, Matti	
	23	08/008,342	1/26/1993	Weiner et al	
	24	08/029,336	3/11/1993	Weiner et al.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 2 OF 4	Attorney Docket No.	TRIPEP.23AUSC2

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	25	WO 90/15070	12/13/1990	Affymax Technologies N.V.		
	26	WO 92/10092	6/25/1992	Affymax Technologies N.V.		
	27	WO 94/11530	5/26/1994	Trustees of Boston University		
	28	WO 94/12305	6/9/1994	Gühning, et al.		
	29	WO 95/11995	5/4/1995	Affymax Technologies N.V.		
	30	WO 96/09805	4/4/1996	Zonagen, INC.		
	31	WO 96/33739	10/31/1996	Smithline Beecham Biologicals S.A.		
	32	WO 97/29212	8/14/1997	Affymetrix, Inc.,		
	33	WO 97/31256	8/28/1997	Louisiana State University		
	34	WO 97/47358	12/18/1997	Merck & Co., Inc.,		
	35	WO 98/34640	8/13/1998	Merck & Co., Inc.,		
	36	WO 03/031588	4/17/2003	Merck & Co., Inc.,		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	37	Abrignani et al., "Perspectives for a vaccine against hepatitis C virus," Journal of Hepatology, 31: (suppl. 1):259-263 (1999)	
	38	Andre et al., "Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage," Journal of Virology, 72(2):1497-1503 (1998)	
	39	Bitter et al., <i>Methods in Enzymol.</i> , 153:516-544 (1987)	
	40	BLASTN 2.2.9., May 1, 2004	
	41	Chang et al., <i>Aliment Pharmacol Ther.</i> 2002 Sep; 16(9): 1623-1632	
	42	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 April 20, 2000	
	43	Colberre-Garapin, et al., "A new dominant hybrid selective marker for higher eukaryotic cells," <i>J. Mol. Biol.</i> 150:1 (1981)	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
	Examiner	Bao Q. Li
SHEET 3 OF 4	Attorney Docket No.	TRIPEP.23AUSC2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	44	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens" <i>Proc Natl. Acad. Sci.</i> , 80:2026-2030 (1983)	
	45	DATABASE GENBANK [Online] 12/02/94, retrieved from NCBI Database accession no.I06434, XP002278035.	
	46	DATABASE REGISTRY [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, 04/17/03, Seq ID No.1, 10 and 11 Claims	
	47	Davis et al., <i>Human Gene Therapy</i> , 4(6):733 (1993)	
	48	Engvall, E., <i>Meth. Enzymol.</i> , 70:419 (1980)	
	49	Fodor et al., <i>Science</i> , 251:767-773 (1991)	
	50	Forns et al., "Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees," <i>PNAS</i> , vol. 97, No. 24, pp. 13318-113323, (2000)	
	51	Hahm et al., "NS3-4A of Hepatitis C Virus is a Chymotrypsin-Like Protease," <i>Journal of Virology</i> , The American Society for Microbiology, 69(4): 2534-2539 (1995).	
	52	Heagy et al., <i>J. Clin. Invest.</i> 1991, Vol. 87, pp. 1916-1924	
	53	Hosoya et al., <i>J. INF. Dis.</i> , 168:641-646 (1993)	
	54	Houghten et al., <i>Proc. Natl. Acad. Sci. USA</i> , 82:51:32 (1985)	
	55	Hultgren et al., <i>Clin. Diagn. Lab. Immunol.</i> 4:630-632 (1997)	
	56	Huse W.D. et al. <i>Science</i> 256:1275-1281 (1989)	
	57	Hutchison et al., <i>Proc. Natl. Acad. Sci. USA</i> 253:6551 (1978)	
	58	Janknecht, et al., <i>Proc. Natl. Acad. Sci. USA</i> 88:8972-8976 (1991)	
	59	Kozbor et al., <i>Immunol Today</i> 4:72 (1983)	
	60	Kumar et al., "Hepatitis C virus genomic RNA for polyprotein gene," <i>Journal of Hepatology</i> , 7:459-465 (2000)	
	61	Lazdina et al., "Humoral and CD4 ⁺ T helper (th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes TH 1-like responses more effectively as a DNA-Based immunogen than as a recombinant protein," <i>Journal of General Virology</i> , 82:1299-1308 (2001)	
	62	Lo, <i>Mol. Cell. Biol.</i> 3:1803-1814 (1983)	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/719,619
	Filing Date	November 20, 2003
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 4 OF 4	Attorney Docket No.	TRIPEP.23AUSC2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	63	Logan & Shenk, <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659	
	64	Lowy, et al., <i>Cell</i> 22:817 (1980)	
	65	Morrison et al. <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855 (1984)	
	66	Mulligan & Berg, <i>Proc. Natl. Acad. Sci. USA</i> 78:2072 (1981)	
	67	NCBI, Genbank, M32084. Hepatitis C Virus. . . [Gi:32987] August 02, 1993	
	68	O'Hare, et al., <i>Proc. Natl. Acad. Sci. USA</i> 78:1527 (1981)	
	69	Orlandi et al., <i>Proc. Natl. Acad. Sci.</i> 86: 3833-3837 (1989)	
	70	Rudikoff et al., <i>Immunology</i> 1982, Vol. 79, pp. 1979-1983	
	71	Ruther et al., <i>EMBO J.</i> , 2:1791 (1983)	
	72	Santerre et al., <i>Gene</i> . 30:147 (1984)	
	73	Steigerwald-Mullen et al., <i>J. Virol.</i> 2000, Vol. 74, No. 15, pp. 6748-6759	
	74	Thompson et al., <i>Cell</i> 56:313-321 (1989)	
	75	Townsend et al., <i>J. Virol.</i> 71:3365 (1997)	
	76	Van der Putten et al., <i>Proc. Natl. Acad. Sci., USA</i> 82:6148-6152 (1985)	
	77	Wigler et al., <i>Cell</i> 11:223 (1977)	
	78	Wigler et al., <i>Proc. Natl. Acad. Sci. USA</i> 77:3567 (1980)	
	79	Winter G. and Milstein C; <i>Nature</i> 349:293-299 (1991)	

3333899
012207

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.